508 related articles for article (PubMed ID: 25284275)
1. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
Gordon KB; Gottlieb AB; Langely RG; van de Kerkhof P; Belasco KT; Sundaram M; Okun M; Serra L
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):767-76. PubMed ID: 25284275
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
Papp K; Crowley J; Ortonne JP; Leu J; Okun M; Gupta SR; Gu Y; Langley RG
Br J Dermatol; 2011 Feb; 164(2):434-41. PubMed ID: 21083543
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
Bissonnette R; Iversen L; Sofen H; Griffiths CE; Foley P; Romiti R; Bachinsky M; Rottinghaus ST; Tan H; Proulx J; Valdez H; Gupta P; Mallbris L; Wolk R
Br J Dermatol; 2015; 172(5):1395-406. PubMed ID: 25418186
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.
Papp K; Menter A; Poulin Y; Gu Y; Sasso EH
J Eur Acad Dermatol Venereol; 2013 May; 27(5):634-42. PubMed ID: 22429586
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.
Umezawa Y; Torisu-Itakura H; Morisaki Y; ElMaraghy H; Nakajo K; Akashi N; Saeki H;
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):568-576. PubMed ID: 30325534
[TBL] [Abstract][Full Text] [Related]
7. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
[TBL] [Abstract][Full Text] [Related]
8. Intermittent etanercept therapy in pediatric patients with psoriasis.
Siegfried EC; Eichenfield LF; Paller AS; Pariser D; Creamer K; Kricorian G
J Am Acad Dermatol; 2010 Nov; 63(5):769-74. PubMed ID: 20833444
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
Gordon K; Papp K; Poulin Y; Gu Y; Rozzo S; Sasso EH
J Am Acad Dermatol; 2012 Feb; 66(2):241-51. PubMed ID: 21752491
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.
Prussick R; Unnebrink K; Valdecantos WC
J Drugs Dermatol; 2015 Aug; 14(8):864-8. PubMed ID: 26267731
[TBL] [Abstract][Full Text] [Related]
11. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
12. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
Danesh MJ; Beroukhim K; Nguyen C; Levin E; Koo J
Dermatol Online J; 2015 Jun; 21(6):. PubMed ID: 26158370
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
[TBL] [Abstract][Full Text] [Related]
15. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
Revicki D; Willian MK; Saurat JH; Papp KA; Ortonne JP; Sexton C; Camez A
Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
[TBL] [Abstract][Full Text] [Related]
17. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
Gniadecki R; Leonardi CL; Gordon KB; Gu Y; Geng Z; Nader A; Teixeira HD
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1297-1304. PubMed ID: 29524255
[TBL] [Abstract][Full Text] [Related]
18. Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study.
Griffiths CE; Luger TA; Brault Y; Germain JM; Mallbris L
J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):468-73. PubMed ID: 25087839
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
